Convalescent Plasma Expanded Access

Objective

Due to the lack of proven treatment options for COVID-19, the only medical intervention currently available to patients who develop severe illness is supportive care. Developing and researching potential treatments in an expedited fashion is a priority in combating this disease. Through collaboration with BloodWorks Northwest, the Mayo Clinic has developed a compassionate use research program that provides patients with severe illness access to investigational convalescent plasma donated by individuals who have recovered from the illness. An individual’s immune system often produces antibodies when exposed to a virus. These antibodies may offer protective benefits if the person is exposed to the virus again in the future. In this research program, individuals who have recovered from COVID-19 donate their plasma, along with the antibodies that it may contain, to patients currently hospitalized with severe or life-threatening illness. Transfusion of antibodies to these patients may improve clinical outcomes and prevent further disease progression.

Principal Investigator

• Todd Freudenberger, MD

Contact

• Email the Clinical Research team

Location

Overlake Medical Center
1035 116th Ave NE 
Bellevue, WA 98004

Phone: (425) 688-5000

Resources

• US COVID Plasma.
• ClinicalTrials.gov: Use NCT04338360 as the identifier to view a full description of this study.
• BloodworksNW.